NCT05593549RecruitingEarly phase 1
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
Source: ClinicalTrials.gov · Last updated 30 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are: * Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function? * Does exposure to high glucose impair autophagy and subsequently microvascular function? Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 18 Oct 2022
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Medical College of Wisconsin
- Diseases
- Type 2 diabetes
- NCT number
- NCT05593549
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 60
- From 1 Jan 2023 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hormone Replacement Therapy
- Use Erectile Dysfunction Medication in the past 6 months
- Use of Topical/non-topical Steroids in last 6 months
- Gender Reassignment Therapy
Other illness
- Uncontrolled hypertension
- Type 1 Diabetes
- Symptomatic coronary artery disease
- Heart Failure
- Renal Impairment
- History of Retinopathy
- Documented Neuromuscular Disorders
- Allergies to Povidone Iodine
- Active Anti-Cancer Treatment or Treatment within last 12 months
- Active COVID-19 or within the past 3 months
Lab values
- Use of anti-coagulant drugs, or anti-platelet drugs
Other
- Current Tobacco use or within last 6 months
- BMI \> 35
- Hyperlipidemia
- Hypercholesterolemia
- Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
- Pregnancy (Young Female subjects)
Who the study is looking for
- Clinical Diagnosis of Type 2 Diabetes Mellitus in accordance with American Diabetes Association (ADA) guidelines (Type 2 Diabetic group)
- Otherwise healthy individuals (Healthy control group) with no more than 1 cardiovascular risk factor
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.